HALO
Halozyme Therapeutics
October 19, 2026 · pre-market open
- Rarity
- 1.67
- Peak move
- −5.85%
- Float cap
- $14.2B
Halozyme Therapeutics is a biopharmaceutical drug-delivery company based in San Diego that licenses its Enhanze technology, built on the proprietary enzyme rHuPH20, to large pharmaceutical partners including Roche, Johnson & Johnson and argenx. Enhanze converts intravenously administered biologics into subcutaneous injections and supports extended dosing intervals, generating royalties on partner product sales. The company also sells its own products, Hylenex and Xyosted, and offers autoinjector and hyperconcentration formulation technologies.
Where do you see this going?
no votes yetVote to see the split.
What we found
no events · 0 from SEC or newswire · 0 timed with the moveNothing found.We searched SEC filings, the newswires and the open web across the three days around this move and found no public information that explains it.